
Investor Relations Presentation





Forward Looking Statements & Non-GAAP Financial Measures

This presentation includes forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management's beliefs and assumptions in light of information currently available to management. Accordingly, the Company's actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in the Company's operations and business environment, including, among other factors, those described in documents filed by the Company with the Securities and Exchange Commission, specifically its Form 10-Ks and 10-Qs. The Company does not assume any obligation to update, amend or clarify such statements to reflect new events, information or circumstances after the date of this presentation.

During the course of this presentation, certain non-GAAP financial information will be presented.

A reconciliation of those numbers to GAAP financial measures is available on the company's website at www.aptar.com on the Investor's page (click on Events & Presentations / Presentations).

Aptar is Part of Essential Critical Infrastructure

- Basic chemicals
- Specialty chemicals
- Agricultural chemicals
- Pharmaceuticals
- Consumer products



Aptar's Products Are Critical During this Time



Sanitizers & Cleaners









Food & Beverage







Engaging with customers and suppliers to ensure the supply chain

Aptar Snapshot














DIVERSE CUSTOMER BASE



A sample of Aptar's 5,000+ global customers

SALES BY MARKET Home Care, Act Packagi







Consolidated Financial Targets

Metric	3 Year Average	2019	Q1 2020	Long-term Target
Core sales growth ¹	5%	3%	-2%	4-7%
Adj. EBITDA ² /Sales %	20%	21%	20%	20-22%
ROIC ³	13%	11%	11%	13-15%
Dividend Payout Ratio	36%	36%	39%	30-40%
Leverage Ratio	≈ 2X	≈ 2X	≈ 2X	1-3X

^{1 –} Excludes acquisitions and currency effects.

^{2 –} Adjusted EBITDA (earnings before net interest, taxes, depreciation and amortization) excludes restructuring costs, acquisition costs, non-recurring purchase accounting adjustments.

^{3 –} Return on invested capital = adjusted earnings before net interest and taxes, less tax effect / average capital (average of beginning of year and end of year capital) [capital = equity plus debt less cash].

^{4 –} Cash dividends paid / adjusted earnings per share.

Q1 Segment Recap and New Product Launches











Aptar Pharma

Core sales growth across each end market; particularly strong growth in our injectables and active packaging businesses

Over 150 projects identified as a result of the COVID-19 pandemic

First commercial launch with PureHale respiratory device for Breathe Free Essentials

US FDA EUA Request for N95 Respirator Decontamination using ActivShieldTM

Aptar Beauty + Home

Negatively impacted by reduced orders from customers providing prestige beauty products, mainly in travel retail and standard retail

Increased demand for hand sanitizers and cleaners was not enough to offset declines in other personal care categories


Spray actuator featured on Lysol Neutra Air Disinfectant Spray and PCR closures and spray pumps featured on a line of Wildwash pet care products


Aptar Food + Beverage

Negatively impacted by the passing on of lower resin costs as well as lower food service and beverage closure sales, which seem to be related to the COVID-19 crisis

Supported Coca-Cola's Powerade product line with a new zero-sugar beverage that features our sport closure

First Quarter 2020 Reported Results





30%
Q1 2019
Reported
Effective Tax
Rate

29% Q1 2020 Reported Effective Tax Rate

Q1 Highlights

- Reported sales and earnings per share were negatively impacted by:
 - Currency exchange rates
 - Timing of passing on lower resin costs
 - COVID-19 pandemic
- Another solid performance by our Pharma segment with core sales growth across each end market with particularly strong growth in our injectables and active packaging businesses
- Beauty + Home was negatively impacted by sales declines in each end market, principally due to COVID-19
- Food + Beverage was negatively impacted by the passing on of lower resin costs as well as COVID-19 related softness


First Quarter 2020 Adjusted EPS and Adjusted EBITDA



28%
Q1 2019
Effective Tax
Rate Adjusted
Earnings*

29%
Q1 2020
Effective Tax
Rate Adjusted
Earnings*

Adjusted Q1 EBITDA



Adjustments:

- 2019: Restructuring initiatives of \$9.5 mil
- 2020: Restructuring initiatives of \$4.8 mil;
 Transaction costs related to acquisitions of \$1.4 mil;
 Purchase accounting adjustments of \$1.4 mil

Q1 Adjusted EPS and Adjusted EBITDA Highlights

- Adjusted EPS and Adjusted EBITDA were negatively impacted by:
 - Reduced volumes and related absorption costs in our Beauty
 + Home and Food + Beverage segments
 - Currency exchange rates
 - \$3.6 million pretax charge for Thank You Awards

Strategic Priorities







Asia





Pharma



Nanopharm O



Talent & Leadership











Excellence Pillars













Transformation









ActivShieldTM



Revenue Near-term Sensitivity

Least Affected Magnitude of Impact Most Affected

	Our Markets	% of Revenue*	Key Drivers
	Pharma	38%	Stable across most medicines and categories; Most prescription drugs and OTC products are easily available for delivery; Potential upside should injectable treatments be developed / grow.
	Home Care	4%	Stable across most categories; Potential upside with increased demand for cleaners.
	Food	10%	Major categories such as Condiments, Dairy and Infant Nutrition are stable; Food Service (certain closures and trays) negatively impacted by confinement and restaurant closings.
	Personal Care	19%	Major categories such as Grooming (including Haircare, Shaving) and Sunscreens are negatively impacted by confinement; Partially offset by higher demand for sanitizers and soaps.
	Beverage	5%	Majority of Beverage business is related to on-the-go beverages, including functional beverages and premium bottled water, all negatively impacted from confinement.
	Beauty	24%	Prestige and Mass Beauty products significantly impacted by reduced travel (travel retail sales), confinement and store closings (less usage, less opportunity to purchase and e-commerce volumes not offsetting retail product sales declines).

Q1: Crisis
Early
Stage

Q2: Crisis Low Point

H2: Gradual Recovery



Cost Containment Actions

- Reducing temporary labor headcount
- Pulling in subcontracted work
- Modifying production schedules
- Regional and site-specific furloughs and wage reductions
- Vacation time being taken
- Eliminated business travel
- Reduced all non-essential spending
- Passing through price adjustm

Liquidity

Debt Structure	 Total debt of \$1.4 billion as of March 31, 2020 Comprised of mainly private placement agreements Average interest rate = 2.6% Fixed / variable = 85% / 15% 		
Near-term Maturities \$56 million maturing in 2020 and 2021 related to our outstanding term loan			
Financial Covenants*	Net Debt/EBITDA = 1.7x → maximum 3.5X EBITDA/Interest Payable =16.3x → minimum 3x Other covenants based on subsidiary debt levels		
Liquidity	 \$411 million in cash and equivalents as of March 31, 2020 (less than half earmarked for FusionPKG acquisition which closed on April 1, 2020) \$100 million capacity (undrawn) on US Revolving Credit Facility €150m capacity (undrawn) on EUR Revolving Credit Facility 		
Working Capital Focus	AP – much closer management of purchases to mirror any reduction in demand from customers and adherence to supplier payment terms. Ongoing supplier payment term negotiations. AR – close monitoring of customer due dates and terms		



Sustainability leader in our industry, committed to accelerate our efforts

One of Barron's Top 100 Most Sustainable U.S. Companies (2019, 2020)

ESG rating of "A"
by MSCI ESG Research
LLC

Sustainability Initiatives











Postconsumer













Better measuring the impacts of existing products

Partnering with global organizations working toward a circular economy

Better identifying **new material opportunities**for future products

We invite you to read our 2018 Corporate Sustainability Report on our website.

Aptar 🚄

Sustainable Solutions





Designed to Recycle











Post Consumer Recycled (Food grade)



- Purpose & Core Values
- Segment Results
- Balanced Capital Allocation
- Relative Performance During Last Recession





We reimagine packaging solutions to improve everyday life for people everywhere.



VISION





We partner with our customers to help them win with differentiated solutions.

We access the expertise of the world to innovate.

We care for our planet.

We have talented, passionate, diverse people who thrive in our inclusive culture.

We always live our Core Values.





We respect and trust people.

We believe in the self-worth of individuals regardless of their status.

We strive for relationships that are based on openness, honesty, and feedback.


We promote teamwork and cooperation at all levels.

We challenge people to develop their potential and to take initiative.

We practice business relationships that are based on responsibility and on long-term and mutual interests to all stakeholders.



Aptar Pharma Today











PATENTS

Approximately

700

Patent Families






biosolutions





MERCK









INNOVATIVE SOLUTIONS










Supporting more than 150 submissions (IND/ANDA/NDA)



Aptar Pharma
Q1 2020
Results



Metric	3 Year Average	2020	Long-term Target
Core sales growth ¹	10%	7%	6-10%
Adj. EBITDA ² margin	35%	37%	32-36%

(1) Excludes acquisitions and currency effects.
 (2) Adjusted EBITDA (earnings before net interest, taxes, depreciation and amortization) excludes restructuring costs, acquisition costs, non-recurring purchase accounting adjustments.



Aptar Beauty + Home Today

































Aptar Beauty + Home Q1 2020 Results



Metric	3 Year Average	2020	Long-term Target
Core sales growth ⁽¹⁾	3%	-9%	3-6%
Adj. EBITDA ⁽²⁾ margin	13%	11%	15-17%

(1) Excludes acquisitions and currency effects.
 (2) Adjusted EBITDA (earnings before net interest, taxes, depreciation and amortization) excludes restructuring costs, acquisition costs, non-recurring purchase accounting adjustments.

Strategic Steps to Strengthen Our Beauty Business



BTY

- Closed on our agreement to acquire a 49% equity interest in BTY
- Leading Chinese manufacturer of high quality, decorative metal components, metalplastic sub-assemblies, and complete color cosmetics packaging solutions for the beauty industry



FusionPKG

- Binding agreement to acquire FusionPKG, leader in high quality, prestige airless and color cosmetics packaging, with conception-to-launch and turnkey solutions for the North American beauty market
- Proven creativity, engineering, formulation and fast go-to-market capabilities – 'fast-beauty'
- Existing relationships with both global cosmetic and skin care customers and with many indie brands
- Potential to scale this beyond North America to other regions



North America Footprint Consolidation

- Closing our Stratford and Torrington,
 Connecticut sites and will absorb and
 rationalize production capacities into other
 North American facilities
- Transfer of production is planned to be completed by the end of the year
- Better positions us to serve our North American Beauty + Home customers and focus on long-term, profitable growth
- Continuation of other steps we have made to streamline our Beauty + Home footprint



Aptar Food + Beverage Today











PEPSICO











Over **Patent Families**




















Aptar Food + Beverage Q1 2020 Results



	3 Year		Long-term
Metric	Average	2020	Target
Core sales growth ⁽¹⁾	5%	-2%	6-10%
Adj. EBITDA ⁽²⁾ Margin	16%	15%	18-21%


(1) Excludes acquisitions and currency effects.
 (2) Adjusted EBITDA (earnings before net interest, taxes, depreciation and amortization) excludes restructuring costs, acquisition costs, non-recurring purchase accounting adjustments.



2015 - 2019 Capital Allocation

Balanced Capital Allocation

Investing in our business and returning value to shareholders















Relative Performance During Last Recession

- Fragrance market tends to be our most economically sensitive
- Strong balance sheet
- Pharma segment is a greater % of our overall business

